Low serum levels of high-density lipoprotein cholesterol and hypolipidaemic treatment

Current Medical Research and Opinion

Volumn 18, Issue 5, 2002, Pages 265-268

  Kolovou, Genovefa D ^a   Cokkinos, Dennis V ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Antiatherogenic effects; Cholesterol; Coronary artery disease; Fibrates; Hypolipidemic treatment; Low HDL C; Metabolism; Statins

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DYSLIPIDEMIA; HUMAN;

ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; RISK FACTORS;

EID: 0036037775     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125000534     Document Type: Article

References (41)

1. Plasma high-density lipoprotein concentration and development of ischaemic heart-disease
2. Associations of serum high density lipoprotein and total cholesterol with total cardiovascular and cancer mortality in a 7-year prospective study of 10,000 men
3. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
4. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
8. Mikhailidis DP Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?
9. Protein-lipid relationships in human plasma
10. Ischemic heart disease, atherosclerosis and longevity
11. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study
12. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)
13. Relation of high-density lipoprotein cholesterol and triglyceride to incidence of atherosclerotic coronary artery disease (The PROCAM experience)
14. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage
15. Monocyte transmigration induced by modification of low density lipoprotein in co-culture of human aortic wall cells is due to induction of monocyte chemotactic protein I and is abolished by high density lipoprotein
16. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium
17. Cholesterol transport between cells and high-density lipoproteins
18. The metabolic pathways of high-density lipoprotein, low density lipoprotein, and triglycerides: A current review
19. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis
20. The ABCs of cholesterol efflux
21. Paraoxonase and coronary heart disease
22. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein
23. High-density lipoprotein: Multipotent effects on cells of the vasculature
24. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation
25. NF-kB: Pivotal mediator or innocent bystander in atherogenesis?
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
27. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
28. The DAIS Project Group and the World Health Organization Collaborating Centre for the Study of Atherosclerosis in Diabetes. Baseline characteristics of the study population in the diabetes atherosclerosis intervention study (DAIS)
29. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
30. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study
31. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
32. Effect of lovastatin on cardiovascular resource utilization and cost in the air force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
33. Statin therapy: Where are we? Where do we go next?
34. Time to look beyond just lowering the serum concentration of low density lipoprotein - High density lipoprotein levels are also important
35. HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin
36. Response of high-density lipoproteins to hypolipidemic drugs according to their initial level
37. Differential response of high-density lipoproteins to first-step lipid-lowering diet according to their initial level
38. The response of high-density lipoproteins to various hypolipidemic interventions depends on their initial level
39. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels
40. Managing the risk of atherosclerosis: The role of high-density lipoprotein
41. Pro and con: High-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management